Talphera, Inc. (TLPH) Stock Price & Analysis
Talphera, Inc. (TLPH) fell 1.46% to USD 1.35 as of July 25, 2026 at 06:46 UTC, according to Nexqual real-time market data.
TLPH last closed at USD 1.37; the session ranged USD 1.31–1.43 on volume of 89,516 shares. Market capitalization is $70.06M, with a 52-week range of USD 0.39–1.57 (NCM). Source: Nexqual, July 25, 2026 at 06:46 UTC.
Key Statistics (as of July 25, 2026 at 06:46 UTC)
| Price | USD 1.35 |
|---|---|
| Change | ▼ 1.46% (down) |
| Previous Close | USD 1.37 |
| Open | USD 1.4 |
| Day Range | USD 1.31 – 1.43 |
| 52-Week Range | USD 0.39 – 1.57 |
| Volume | 89,516 shares |
| Market Cap | $70.06M |
| Exchange | NCM |
Technical Analysis (TLPH)
Nexqual's technical model rates TLPH "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:46 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.72 (neutral) |
| vs SMA50 | Above (USD 1.03) |
| MACD | 0.1 (positive) |
Analyst Ratings (TLPH)
Wall Street analysts rate TLPH "None" based on 3 analysts, with a mean price target of USD 3.17 (range USD 3–3.5), per Nexqual as of July 25, 2026 at 06:46 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.17 |
| High Target | USD 3.5 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (TLPH)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.08 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.1 vs est -0.12 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Financials & Fundamentals (TLPH)
| Total Revenue | $1,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1451600.00% |
| Profit Margin | +0.00% |
| ROE | -118.40% |
| Debt / Equity | 35.17 |
| Current Ratio | 5.3 |
| Total Cash | $21.11M |
| Total Debt | $6.50M |
| Free Cash Flow | $-5.76M |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Financial Health Score (TLPH)
Nexqual rates Talphera, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $21M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -118%, ROA -40.2% |
Ownership (TLPH)
| Insider Ownership | +21.42% |
|---|---|
| Institutional Ownership | +34.76% |
| Shares Outstanding | 51.90M |
| Float | 26.98M |
| Short % of Float | +2.09% |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
Leadership (TLPH)
Talphera, Inc. is led by Vincent J. Angotti (age 57), CEO & Director, per Nexqual as of July 25, 2026 at 06:46 UTC.
| CEO & Director | Vincent J. Angotti (age 57) |
|---|---|
| Chief Financial Officer | Raffi Mark Asadorian (age 56) |
Major Backers & Investors (TLPH)
Notable institutional backers of Talphera, Inc. include AIGH Capital Management LLC, Rock Springs Capital Management, LP, Nantahala Capital Management, LLC, according to Nexqual as of July 25, 2026 at 06:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.98% |
| Rock Springs Capital Management, LP | 6.92% |
| Nantahala Capital Management, LLC | 6.73% |
| Rosalind Advisors, Inc. | 6.46% |
| Bleichroeder LP | 2.52% |
| Cantor Fitzgerald, L.P. | 1.71% |
| Empery Asset Management, LP | 1.14% |
| Caption Management, LLC | 1.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.7% |
Source: Nexqual, July 25, 2026 at 06:46 UTC.
From Talphera, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
- The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
- It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VSTM | Verastem, Inc. | USD 6.05 | ▲ 2.72% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 9.88 | ▼ 6.7% |
| BLRX | BioLineRx Ltd. | USD 2.82 | ▼ 1.05% |
| OGEN | Oragenics Inc. | USD 0.51 | ▼ 3.58% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:46 UTC. This page is informational and not investment advice.